| Methods used in the spatial analysis of tuberculosis epidemiology: a systematic review D Shaweno, M Karmakar, KA Alene, R Ragonnet, ACA Clements, ... BMC medicine 16, 1-18, 2018 | 107 | 2018 |
| Empirical ways to identify novel Bedaquiline resistance mutations in AtpE M Karmakar, CHM Rodrigues, KE Holt, SJ Dunstan, J Denholm, ... PloS one 14 (5), e0217169, 2019 | 62 | 2019 |
| ThermoMutDB: a thermodynamic database for missense mutations JS Xavier, TB Nguyen, M Karmarkar, S Portelli, PM Rezende, JPL Velloso, ... Nucleic acids research 49 (D1), D475-D479, 2021 | 60 | 2021 |
| Structure guided prediction of Pyrazinamide resistance mutations in pncA M Karmakar, CHM Rodrigues, K Horan, JT Denholm, DB Ascher Scientific reports 10 (1), 1875, 2020 | 60 | 2020 |
| Analysis of a Novel pncA Mutation for Susceptibility to Pyrazinamide Therapy M Karmakar, M Globan, JAM Fyfe, TP Stinear, PDR Johnson, NE Holmes, ... American journal of respiratory and critical care medicine 198 (4), 541-544, 2018 | 39 | 2018 |
| Hyper transmission of Beijing lineage Mycobacterium tuberculosis: systematic review and meta-analysis M Karmakar, JM Trauer, DB Ascher, JT Denholm Journal of Infection 79 (6), 572-581, 2019 | 36 | 2019 |
| Quantifying the rates of late reactivation tuberculosis: a systematic review KD Dale, M Karmakar, KJ Snow, D Menzies, JM Trauer, JT Denholm The Lancet Infectious Diseases 21 (10), e303-e317, 2021 | 32 | 2021 |
| In Silico-Based High-Throughput Screen for Discovery of Novel Combinations for Tuberculosis Treatment R Singh, V Ramachandran, R Shandil, S Sharma, S Khandelwal, ... Antimicrobial Agents and Chemotherapy 59 (9), 5664-5674, 2015 | 9 | 2015 |
| HGDiscovery: an online tool providing functional and phenotypic information on novel variants of homogentisate 1, 2-dioxigenase M Karmakar, V Cicaloni, CHM Rodrigues, O Spiga, A Santucci, DB Ascher Current Research in Structural Biology 4, 271-277, 2022 | 8 | 2022 |
| Identifying Genotype–Phenotype Correlations via Integrative Mutation Analysis E Airey, S Portelli, JS Xavier, YC Myung, M Silk, M Karmakar, JPL Velloso, ... Artificial Neural Networks, 1-32, 2021 | 5 | 2021 |
| A comprehensive computational platform to guide drug development using graph-based signature methods DEV Pires, S Portelli, PM Rezende, WNP Veloso, JS Xavier, M Karmakar, ... Structural Bioinformatics: Methods and Protocols, 91-106, 2020 | 5 | 2020 |
| Exploring protein supersecondary structure through changes in protein folding, stability, and flexibility DEV Pires, CHM Rodrigues, ATS Albanaz, M Karmakar, Y Myung, ... Protein Supersecondary Structures: Methods and Protocols, 173-185, 2019 | 5 | 2019 |
| Estimating tuberculosis drug resistance amplification rates in high-burden settings M Karmakar, R Ragonnet, DB Ascher, JM Trauer, JT Denholm BMC Infectious Diseases 22 (1), 82, 2022 | 2 | 2022 |
| Uncovering the molecular drivers of NHEJ DNA repair-implicated missense variants and their functional consequences R Al-Jarf, M Karmakar, Y Myung, DB Ascher Genes 14 (10), 1890, 2023 | 1 | 2023 |
| Bioinformatics Approaches to Predict Mutation Effects in the Binding Site of the Proangiogenic Molecule CD93 V Cicaloni, M Karmakar, L Frusciante, F Pettini, A Visibelli, M Orlandini, ... Frontiers in Bioinformatics 2, 891553, 2022 | 1 | 2022 |
| Concepts and methods for predicting viral evolution M Meijers, D Ruchnewitz, J Eberhardt, M Karmakar, M Łuksza, M Lässig bioRxiv, 2024.03. 19.585703, 2024 | | 2024 |
| HGDiscovery: an online tool providing functional and phenotypic information on novel variants of homogentisate 1, 2-dioxigenase M Karmakar, V Cicaloni, CHM Rodrigues, O Spiga, A Santucci, DB Ascher bioRxiv, 2021.04. 26.441386, 2021 | | 2021 |
| Mycobacterium tuberculosis genome mutations and fitness cost: molecular and epidemiological modelling of functional implications M KARMAKAR | | 2021 |
| Current Research in Structural Biology M Karmakar, V Cicaloni, CHM Rodrigues, O Spiga, A Santucci, DB Ascher | | |
